Respiratory symptoms and sensitisation in subjects exposed to sodium bisulfite treated (1% solution) Norwegian lobsters

O. Omland, S. Viskum, A. M. Thulstrup, T. Sigsgaard (Aalborg, Aarhus, Denmark)

Source: Annual Congress 2003 - Work-related asthma and allergy
Session: Work-related asthma and allergy
Session type: Thematic Poster Session
Number: 3074
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Omland, S. Viskum, A. M. Thulstrup, T. Sigsgaard (Aalborg, Aarhus, Denmark). Respiratory symptoms and sensitisation in subjects exposed to sodium bisulfite treated (1% solution) Norwegian lobsters. Eur Respir J 2003; 22: Suppl. 45, 3074

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
IL-1β in exhaled breath condensate is associated to work related cough and sensitisation in subjects exposed to sodium bisulfite treated (1% solution) Norwegian lobsters
Source: Eur Respir J 2004; 24: Suppl. 48, 369s
Year: 2004

Audit of once daily nebulised hypertonic 6% saline (HTS) in adult bronchiectasis
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010

Induced sputum (IS) in asthmatic hairdressers sensitized to ammonium persulphate (AP)
Source: Annual Congress 2003 - Occupational asthma
Year: 2003


Inhalation therapy with hypertonic saline (3%) – A treatment option for airway disease in children?
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015


Clinical surveys with nebulised hypertonic saline (HS) in CF children
Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Year: 2020


A single blind study to compare nebulised hypertonic saline (7%) and normal saline (0.9%) as an adjunct to physiotherapy airway clearance in patients with bronchiectasis
Source: Eur Respir J 2005; 26: Suppl. 49, 304s
Year: 2005

Efficacy of nasal wash with saline solution 2% NaCl in children with high nasal resistance
Source: Eur Respir J 2001; 18: Suppl. 33, 120s
Year: 2001

A case series of 55 housewives with reactive airways dysfunction syndrome following exposure to a mixture of sodium hypochlorite and hydrochloric acid
Source: Eur Respir J 2002; 20: Suppl. 38, 129s
Year: 2002

Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016


Bronchial challenge test with 10% potassium chloride as an alternative in diagnosis of bronchial asthma in remission – a summary of 10 years of experience
Source: Eur Respir J 2006; 28: Suppl. 50, 680s
Year: 2006

Chronic inhalation toxicity study of nebulized alpha1 proteinase inhibitor (alpha1-PI), TAL6005, in rodents
Source: Annual Congress 2010 - Models of airways disease
Year: 2010


Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples
Source: Eur Respir J 2005; 26: Suppl. 49, 595s
Year: 2005

Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


Montelukast sodium (MS) in addition to sodium cromoglycate (SCG) on the airway response to the same cumulative dose of inhaled mannitol
Source: Eur Respir J 2005; 26: Suppl. 49, 370s
Year: 2005

Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013


Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017



Validation of the asthma control questionnaire in children (6-16 years)
Source: Annual Congress 2009 - Clinical advances in childhood asthma
Year: 2009


Effects of sodium chloride high concentrated solution inhalations in patients with chronic non-allergic obstructive bronchopulmonary diseases
Source: Annual Congress 2008 - Mucociliary clearance, novel techniques and assessments, in adult, paediatric and mechanically ventilated patients
Year: 2008

Severe asthma (SA) compared to non severe persistent asthma (PA) in children: An Italian on-line database
Source: International Congress 2014 – Paediatric epidemiology: wheeze, asthma and other respiratory diseases
Year: 2014

The impact of depression in patients with severe asthma (SA) in the Wessex Severe Asthma Cohort (WSAC)
Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD
Year: 2020